Practice Updates in Adjuvant Immune Checkpoint Inhibition for Bladder Cancer : Episode 10

Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing

March 19, 2025

Opinion

Video

An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts treatment selection by offering improved convenience and accessibility, particularly in advanced/metastatic and perioperative settings. SC formulations may reduce costs, time, and patient burden while enhancing treatment compliance and follow-up.

EP: 1.MIUC: Risk of Recurrence After Radical Cystectomy

EP: 2.High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

EP: 3.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design

EP: 4.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results

EP: 5.Dr. Galsky’s Perspectives on the CheckMate 274 Data Results

EP: 6.Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies

EP: 7.Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting

EP: 8.Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management

EP: 9.Adjuvant ICI for High-Risk MIUC: Patient Counseling

Now Viewing

EP: 10.Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing

Video content above is prompted by the following:

How does availability of SC ICI impact treatment selection for your patients with bladder cancer? (NCCN 6.2024; Albiges 2025; Burotto 2024)
- In the advanced/metastatic setting
- In the perioperative setting
- From a practical standpoint, what potential cost and time savings could your center anticipate with SC ICI formulations?
- How might an SC option alleviate patient burden in treatment accessibility, compliance, and follow-up?